Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Ceftobiprole medocaril sodium
Correvio UK Ltd
J01DI01
Ceftobiprole medocaril sodium
500mg
Powder for solution for infusion
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 05010201; GTIN: 7640137530938
1 PACKAGE LEAFLET This medicine is subject to additional monitoring. This will allow quick identification of new information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects READ ALL OF THIS LEAFLET CAR INFORMATION FOR YOU - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your - If you get any side effects, listed in this leaflet. WHAT IS IN THIS LEAFLET 1. What Zevtera is and what it is used for 2. What you need to know before 3. How to use Zevtera 4. Possible side effects 5. How to store Zevtera 6. Contents of the pack and other 1. WHAT Zevtera is an antibiotic medicine that contains the active substance to a group of medicines called Zevtera is used to treat adults with infections of the lungs called ‘pneumonia’. Zevtera works by killing certain bacteria, which can cause serious lung infections. 2. WHAT YOU DO NOT USE - if you are allergic to (listed in section - if you are allergic to other - if you have had previous severe allergic reactions Do not use Zevtera being given WARNINGS AND PRECAUTIONS Talk to your doctor - if you have kidney - if you have ever had any allergic reactions to other antibiotics like penicillin or carbapenem - if you have ever had fits (seizures or convulsions) - if you have d inflammation of the bowel known as ‘colitis’). FIRST CHECKING WITH YOUR DOCTOR - if you are HIV positive - if your immune system is severely weakened - if your white blood counts are very low or your bone marrow function is suppressed ZEVTERA This medicine is subject to additional monitoring. This will allow quick identification of new information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects READ ALL OF THIS LEAFLET CAR INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your If you get any side effects, listed in this leaflet. WHAT IS IN THIS LEAFLET What Zevtera is and what Read the complete document
OBJECT 1 ZEVTERA 500 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION Summary of Product Characteristics Updated 18-Nov-2015 | Basilea Pharmaceutica International Ltd This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. Name of the medicinal product Zevtera 500 mg powder for concentrate for solution for infusion. 2. Qualitative and quantitative composition Each vial contains 500 mg of ceftobiprole (as 666.6 mg ceftobiprole medocaril sodium). After reconstitution, each mL of concentrate contains 50 mg ceftobiprole (as 66.7 mg of ceftobiprole medocaril sodium). Excipient (s) with known effect: Each vial contains approximately 1.3 mmol (29 mg) sodium. For a full list of excipients, see section 6.1. 3. Pharmaceutical form Powder for concentrate for solution for infusion. White, yellowish to slightly brownish, cake to broken cake or powder. The pH of the reconstituted solution is between 4.5 and 5.5. 4. Clinical particulars 4.1 Therapeutic indications Zevtera is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1): - Hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP) - Community-acquired pneumonia (CAP) Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Posology The recommended dose of Zevtera is 500 mg administered as a 2-hour intravenous infusion every 8 hours. For CAP, a switch to an appropriate oral antibiotic may be considered after completion of at least 3 days of intravenous ceftobiprole medocaril sodium treatment, depending on the patient's clinical response. _Paediatric population_ The safety and efficacy of Zevtera in children aged birth to < 18 years have not yet been established. Zevtera is not recommended for use in children or adolescents be Read the complete document